1. Use of an anti-IL-l α ~~Ab~~ antibody in ~~preparation~~ the manufacture of a medicament for treating a ~~tumor-associated~~neoplastic disease in a human subject.

2. The use according to claim 1, wherein the anti-IL-l α ~~Ab~~ antibody is a ~~mAb~~monoclonal antibody.

3. The use according to claim 2, wherein the ~~mAb~~ monoclonal antibody is MABp1~~an IgGl~~.

4. The use according to claim ~~2~~1, wherein the ~~mAb comprises a complementarity determining region of MABp 1.~~neoplastic disease is a colorectal cancer.

~~5. The use according to claim 2, wherein the mAb is MABpl .~~

~~6. The use according to claim 1, wherein the tumor-associated disease is a colorectal tumor-associated disease.~~

~~7~~5. The use according to claim 1, wherein the ~~tumor-associated~~neoplastic disease is a KRAS-mutated ~~tumor-associated disease~~cancer.

~~8~~6. The use according to claim 1, wherein the ~~tumor-associated~~neoplastic disease is associated with EBV infection.

~~9~~7. The use according to claim 1, wherein the ~~tumor-associated~~neoplastic disease is nasopharyngeal cancer.

~~10~~8. The use according to claim 1, wherein the neoplastic~~tumor-associated~~ disease is lung cancer.

~~1 1~~9. The use according to claim 1, wherein the ~~tumor-associated~~neoplastic disease is a non-cancerous condition associated with blood cell neoplasms.

~~12~~10. The use according to claim 1, wherein the ~~tumor-associated~~neoplastic disease is Castleman's disease.

~~13~~11. Use of an anti-IL-l α ~~Ab~~ antibody in ~~preparation~~ the manufacture of a medicament for ~~decreasing~~ reducing the size of a tumor in a human ~~subject~~cancer patient.

~~14. Use of an anti-IL-l α Ab in preparation of a medicament to decrease edema in a human subject.~~

~~15. Use of an anti-IL-l α Ab in preparation of a medicament to decrease neuropathy in a human subject.~~

12. The use of claim 11, wherein the human cancer patient is one whose cancer has progressed after treatment with chemotherapy, radiotherapy, or biologic agents.